Hong Kong · Delayed Price · Currency is HKD Everest Medicines Company Description
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.
Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; and Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator which is in phase 3 clinical trial for to treat moderate-to-severe active ulcerative colitis.
The company provides Zetomipzomib, an immunoproteasome inhibitor that is in phase 2b clinical trial, for a range of immune mediated disorders, including lupus nephritis; EVER001, a covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor which is in the phase 1b clinical trial for the treatment of renal diseases; and mRNA platform therapeutic vaccines for cancer and autoimmune diseases.
Further, it offers EVER206, a polymyxin derivative designed to treat f MDR gram negative bacterial infections reduce toxicity and nephrotoxicity which is in phase 1 of clinical trial.
The company was incorporated in 2017 and is based in Shanghai, China.
| Country | Cayman Islands |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 665 |
| CEO | Yongqing Luo |
Contact Details
Address: CITIC Pacific Plaza, 16/F Shanghai, 200041 China | |
| Website | everestmedicines.com |
Stock Details
| Ticker Symbol | 1952 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG3224E1061 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Yongqing Luo | Chief Executive Officer |
| Ian Ying Woo | Chief Financial Officer |